RWE AG ADS (RWEOY) Financials Nov 14, 2014, 8:10
RWE AG ADS (RWEOY) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for RWE AG ADS
Fiscal year is January-December. All values EUR millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 46.19B 50.72B 49.15B 50.77B 51.39B
Cost of Goods Sold (COGS) incl. D&A 36.62B 41.11B 41.63B 39.53B 44B
COGS excluding D&A 34.27B 37.91B 38.86B 36.55B 41.19B
Depreciation & Amortization Expense 2.35B 3.2B 2.77B 2.97B 2.81B
Depreciation 1.9B 2.6B 2.21B 2.5B 2.49B
Amortization of Intangibles 449M 603M 564M 476M 313M
Gross Income 9.57B 9.61B 7.52B 11.25B 7.39B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 2.07B 2.21B 1.44B 2.7B 3.34B
Research & Development 110M - - - -
Other SG&A 1.96B 2.21B 1.44B 2.7B 3.34B
Other Operating Expense 812M 1.91B 1.16B 669M 375M
Unusual Expense 53M (9M) 2.19B 4.63B 4.75B
EBIT after Unusual Expense (53M) 9M (2.19B) (4.63B) (4.75B)
Non Operating Income/Expense (641M) (123M) 411M (519M) (114M)
Non-Operating Interest Income 691M 548M 555M 491M 394M
Equity in Affiliates (Pretax) 131M - - - -
Interest Expense 1.22B 1.26B 1.06B 1.25B 1.07B
Gross Interest Expense 1.22B 1.26B 1.11B 1.34B 1.14B
Interest Capitalized - 0 50M 86M 68M
Pretax Income 5.6B 4.67B 2.62B 1.97B (1.87B)
Income Tax 1.86B 1.38B 854M 526M 956M
Income Tax - Current Domestic 1.76B 2.06B 630M 867M 856M
Income Tax - Current Foreign - - - - -
Income Tax - Deferred Domestic 97M (680M) 224M (341M) 100M
Income Tax - Deferred Foreign - - - - -
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 310M 400M 261M 384M
Other After Tax Income (Expense) - 0 0 0 0
Consolidated Net Income 3.74B 3.6B 2.17B 1.7B (2.44B)
Minority Interest Expense 260M 294M 364M 398M 314M
Net Income 3.48B 3.31B 1.81B 1.31B (2.76B)
Extraordinaries & Discontinued Operations 91M 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations 91M 0 0 0 0
Net Income After Extraordinaries 3.57B 3.31B 1.81B 1.31B (2.76B)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 3.48B 3.31B 1.81B 1.31B (2.76B)
EPS (Basic) 6.68 6.18 3.35 2.13 (4.49)
Basic Shares Outstanding 534.91M 535.34M 538.97M 614.48M 614.75M
EPS (Diluted) 6.68 6.18 3.35 2.13 (4.49)
Diluted Shares Outstanding 534.91M 535.34M 538.97M 614.48M 614.75M
EBITDA 9.04B 8.7B 7.68B 10.85B 6.48B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...
Continue Reading
Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...
Continue Reading
Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...
Continue Reading
A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...
Continue Reading
Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...
Continue Reading
Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...
Continue Reading
Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...
Continue Reading
New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...
Continue Reading
Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...
Continue Reading
Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...
Continue Reading
Top 5 Most Recently Viewed Articles
Grand Circle Cruise Line Recognized Among the Best Grand Circle Cruise Line (GCCL) recently earned the impressive title of #2 Best River Cruise Line in the Travel + Leisure's 2025 World's Best Awards. This accolade showcases the hard work and dedication of the teams and crew members who make each journey remarkable along Europe’s scenic rivers. Celebrating a Special...
Continue Reading
Lancaster Resources Secures Approval for Exploration License Vancouver-based Lancaster Resources Inc. (CSE:LCR) (OTC:LANRF) (FRA:6UF0) is pleased to announce a significant milestone in its gold exploration journey. The company has received confirmation of an Exploration License for the Lake Cargelligo Gold Project from the State of New South Wales. Covering an impressive...
Continue Reading
Understanding the Vitrectomy Devices Market Growth The vitrectomy devices industry has become increasingly vital in treating various eye-related disorders, with significant growth projected in the coming years. By focusing on technological advancements and heightened awareness of eye health, the market is set to expand impressively. According to a recent report, the...
Continue Reading
Understanding RDG Mining's Latest Offerings In recent times, the popularity of cryptocurrency has surged significantly, with platforms like RDG Mining capitalizing on this trend. RDG Mining is a leading cloud mining service based in the UK that has captured the interest of over 7.5 million users globally, particularly with the rise in various cryptocurrencies, including...
Continue Reading
Revisions to Financial Reporting and Calendar The board of Pharma Equity Group A/S has recently made the strategic decision to submit only half-yearly financial reports moving forward. This adjustment reflects a shift in focus towards more impactful reporting. As a result, the financial calendar for 2025 has been updated to better align with these new reporting practices....
Continue Reading